Nubeqa

Pharma

FDA approves use of Bayer's Nubeqa in all patients with mCSPC

Bayer has scored an important FDA label expansion for Nubeqa, which now can be used by all patients with metastatic castration-sensitive prostate cancer.

Kevin Dunleavy Jun 4, 2025 11:38am

Bayer weathers LOE for Xarelto with success of Kerendia, Nubeqa

May 13, 2025 11:25am

Bayer projects Xarelto's sales decline will gain steam in 2025

Mar 5, 2025 11:17am

JPM25: Bayer gears up for 'must-win battles' amid Xarelto decline

Jan 15, 2025 8:00pm

Bayer's 'transition year' looms as Xarelto sales falter

Nov 12, 2024 3:03pm

Bayer proposes Nubeqa chemo-free regimen in prostate cancer type

Sep 16, 2024 4:15am